Earnings ·
Viridian reports Q3 net product revenue of $24.7 million for Lumvoa
VRDNViridian Therapeutics, Inc.\DE
Viridian Therapeutics reported third-quarter 2026 financial results showing $24.7 million in net product revenue from its thyroid eye disease treatment, Lumvoa, with more than 100 patients on therapy as of September 30, 2026. The company recorded a net loss of $101.2 million compared to $34.6 million in the prior-year period, driven by increased selling, general and administrative expenses related to commercial activities for Lumvoa. Research and development expenses decreased to $70.1 million from $86.3 million. The company held $955.2 million in cash, cash equivalents, and marketable securities at quarter-end. Viridian Therapeutics is a biotechnology company focused on discovering, developing, and commercializing medicines for autoimmune and rare diseases.